Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiomorpholinomethylenediphosphonic Acid SCHEMBL10345507 | 0.98 | FDPS (0.95) | FDPS | |
| SCHEMBL10346154 | 0.92 | FDPS (0.84) | FDPS | |
| Thiomorpholinomethylenediphosphonic Acid SCHEMBL10345508 | 0.86 | FDPS (0.74) | FDPS | |
| SCHEMBL203348 | 0.82 | FDPS (0.75) | FDPS | |
| SCHEMBL898693 | 0.82 | FDPS (0.75) | FDPS | |
| SCHEMBL3080928 | 0.82 | FDPS (0.75) | FDPS | |
| SCHEMBL2203676 | 0.77 | FDPS (0.85) | FDPS | |
| SCHEMBL2472093 | 0.75 | FDPS (1.00) | FDPS | |
| N-(Hexamethyleneimino)Methylenebisphosphonic Acid SCHEMBL12309768 | 0.75 | FDPS (1.00) | FDPS | |
| SCHEMBL9356971 | 0.73 | FDPS (0.62) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915239-B2 | Treating lameness with an osseous and/or articular component which appear in a person or animal not suffering from fractures or arthritis; horses; veterinary medicine; bone disorders, osteoarthritis | CEVA SANTE ANIMALE (FR) | 2011-03-29 | — | — | US | claimed |
| EP-1120117-B1 | Method of increasing the production of eggs and strengthening eggshells in poultry | CEVA SANTE ANIMALE (FR) | 2007-09-12 | — | — | EP | claimed |
| US-20060183717-A1 | Process for treating lameness with an osseous, articular or osteoarticular component in human or veterinary medicine, comprising the administration of a bisphosphonic acid derivative | CEVA SANTE ANIMALE | 2006-08-17 | — | — | US | claimed |
| EP-1117410-B1 | USE OF BISPHOSPHONIC ACID DERIVATIVES FOR PREPARING A MEDICINE FOR TREATING LAMENESS | CEVA SANTE ANIMALE (FR) | 2005-12-28 | — | — | EP | claimed |
| US-20040110726-A1 | Process for treating lameness administration of a bisphosphonic acid derivative | CEVA SANTE ANIMALE | 2004-06-10 | — | — | US | claimed |
| US-6696429-B2 | ESPECIALLY DUE TO OSTEOARTHROSIS, OSTEOCHONDROSIS, NAVICULAR DISEASE OR ENTHESOPATHY OF THE BONY INSERTIONS OF THE TENDONS, OF THE LIGAMENTS, OR OF THE APONEUROSIS, PARTICULARLY IN HORSES | CEVA SANTE ANIMALE (FR) | 2004-02-24 | — | — | US | claimed |
| US-20030032627-A1 | Process for treating lameness by administration of a bisphosphonic acid derivative | SANOFI SANTE NUTRITION ANIMALE | 2003-02-13 | — | — | US | claimed |
| US-20030013685-A1 | Process for increasing the egg production and strengthening the eggshells of poultry | CEVA SANTE ANIMALE (FR) | 2003-01-16 | — | — | US | claimed |
| US-6455514-B2 | HUMAN OR VETERINARY MEDICINE, ESPECIALLY HORSES, INVOLVING LAMENESS WITH AN OSSEOUS, ARTICULAR OR OSTEOARTICULAR COMPONENT AND NOT INVOLVED WITH ARTHRITUS OR FRACTURES; NO INCREASE IN BONE DENSITY; E.G., TILUDRONIC ACID AND SALTS | CEVA SANTE ANIMALE (FR) | 2002-09-24 | — | — | US | claimed |
| EP-0623347-B1 | Use of bisphosphoric acid derivatives for the manufacture of a medicament to improvement bone repair | SANOFI SYNTHELABO (FR) | 2001-10-31 | — | — | EP | claimed |
| US-20010006960-A1 | PROCESS FOR TREATING LAMENESS BY ADMINISTRATION OF A BISPHOSPHONIC ACID DERIVATIVE | CEVA SANTE ANIMALE (FR) | 2001-07-05 | — | — | US | claimed |
| EP-0998934-A1 | REMEDIES FOR INTRAMEDULLARY DISEASES | TORAY INDUSTRIES, INC. (JP) | 2000-05-10 | — | — | EP | claimed |
| EP-0336851-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING A DIPHOSPHONIC ACID DERIVATIVE | ELF SANOFI (FR) | 1992-03-18 | — | — | EP | claimed |
| US-4980171-A | AND SODIUM LAURYL SULFATE; EXCELLENT BIOAVAILABILITY; BONE DISORSERS, ANTIARTHRETIC | SOCIETE ANONYME DITE : SANOFI (FR) | 1990-12-25 | — | — | US | claimed |
| EP-0248854-B1 | NOVEL BISPHOSPHONIC DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1990-04-25 | — | — | EP | claimed |
| US-4870063-A | Bisphosphonic acid derivatives, their production and use | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1989-09-26 | — | — | US | claimed |
| EP-0276288-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A BISPHOSPHONATE AND THEIR USE FOR NASAL ADMINISTRATION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1988-08-03 | — | — | EP | claimed |
| WO-1988000829-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A BISPHOSPHONATE AND THEIR USE FOR NASAL ADMINISTRATION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) | 1988-02-11 | — | — | WO | claimed |
| EP-0248854-A1 | NOVEL BISPHOSPHONIC DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION. | LEO PHARM PROD LTD (DK) | 1987-12-16 | — | — | EP | claimed |
| WO-1987003598-A1 | NOVEL BISPHOSPHONIC DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1987-06-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183717-A1 | Process for treating lameness with an osseous, articular or osteoarticular component in human or veterinary medicine, comprising the administration of a bisphosphonic acid derivative | SLC16A1, SLC26A4, SLCO4C1 | FDPS 703/4885 |
| US-20030032627-A1 | Process for treating lameness by administration of a bisphosphonic acid derivative | SLC16A1, CLIC1, SLC16A3 | FDPS 1138/4885 |
| US-20010006960-A1 | PROCESS FOR TREATING LAMENESS BY ADMINISTRATION OF A BISPHOSPHONIC ACID DERIVATIVE | SLC16A1, CLIC1, SLC16A3 | FDPS 1138/4885 |
| US-20030013685-A1 | Process for increasing the egg production and strengthening the eggshells of poultry | ALPP, FABP6, BMP6 | FDPS 298/4885 |
| US-20040110726-A1 | Process for treating lameness administration of a bisphosphonic acid derivative | SLC16A1, SLC16A3, CLIC1 | FDPS 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.